System for optimizing the enzymatic synthesis of beta-lactam antibiotics from penicillin G.

Abstract

An automated system for the enzymatic synthesis of beta-lactam antibiotics from penicillin G, comprising: an enzymatic bioreactor configured for continuous flow operation in which penicillin G acylase (PGA) is immobilized on a porous support selected from agarose, functionalized silica nanoparticles, polymeric hydrogels or magnetic nanoparticles, thereby ensuring prolonged enzyme stability, controlled diffusion and prevention of enzyme washout; a sensor array embedded in the bioreactor for real-time monitoring, comprising optical, electrochemical, spectrophotometric and fluorescence resonance energy transfer (FRET) based sensors, with the sensors continuously measuring reaction parameters such as pH, temperature, substrate concentration, enzyme activity and product formation rate; an adaptive control unit comprising a microprocessor-controlled, artificial intelligence (AI)-based predictive model, wherein the control unit dynamically adjusts the substrate flow rate, buffer composition, temperature regulation, modulation of enzyme activity and pH titration in response to real-time sensor data, thus ensuring optimal enzymatic efficiency and sustained yield of 6-aminopenicillanic acid (6-APA); a product separation unit downstream of the bioreactor based on microfiltration, in which a selective membrane filtration system isolates 6-APA from unreacted penicillin G and by-products, thus enabling continuous recovery and purification of the desired antibiotic intermediate; an automated substrate recycling module in which unconverted penicillin G is recovered and reintroduced into the bioreactor via an integrated spectrophotometric quantification system, with the system measuring the residual substrate concentration and dynamically adjusting the recycling flow rates to maximize substrate utilization and minimize waste; an enzyme regeneration module comprising a controlled buffer washing and reactivation mechanism that periodically restores enzymatic activity by means of stabilizing agents selected from polyols, amino acid derivatives or cofactor solutions, wherein the regeneration module also includes an ultrasonic wave activation system to prevent enzyme aggregation and restore the native conformation of the immobilized PGA; a blockchain-based data logging system in which all process parameters, enzyme activity measurements, reaction conditions and production yields are recorded in an immutable decentralized ledger to ensure compliance with regulations, traceability and process safety; A scalable, modular bioreactor architecture in which several interconnected enzymatic reactor units operate in parallel. Each bioreactor is independently controlled but synchronized with the central, AI-based process optimization module, enabling flexible, demand-driven scalability of production.

Description

FIELD OF THE INVENTION

[0001] The present invention relates to a system and a method for optimizing the enzymatic synthesis of beta-lactam antibiotics from penicillin G. In particular, it is a novel system that improves the efficiency, yield and purity of beta-lactam antibiotics such as amoxicillin or cephalexin through an automated enzymatic reactor with real-time monitoring and process optimization. BACKGROUND OF THE INVENTION

[0002] Beta-lactam antibiotics, including penicillins and cephalosporins, represent an important class of antimicrobial agents used in modern medicine. Conventional synthesis of these antibiotics involves enzymatic catalysis with penicillin G acylase (PGA) to convert penicillin G to 6-aminopenicillanic acid (6-APA), a key intermediate for semisynthetic beta-lactam antibiotics. The enzymatic reaction is extremely sensitive to factors such as pH, temperature, enzyme concentration, and substrate concentration, which affect yield and purity. Conventional batch processes suffer from inefficiency, enzyme degradation, and inconsistent product quality. Therefore, there is a need for an advanced, automated system that ensures optimal reaction conditions to maximize productivity while reducing operating costs and waste.

[0003] The enzymatic synthesis of beta-lactam antibiotics from penicillin G has been an essential aspect of drug manufacturing for decades. Beta-lactam antibiotics, including penicillins and cephalosporins, are among the most widely used antimicrobials due to their broad spectrum of activity and efficacy against bacterial infections. The production of these antibiotics involves the enzymatic hydrolysis of penicillin G, resulting in the formation of 6-aminopenicillanic acid (6-APA), a key intermediate in the synthesis of semisynthetic antibiotics such as amoxicillin and cephalexin. The enzymatic reaction is catalyzed by penicillin G acylase (PGA), an enzyme that selectively hydrolyzes the acyl side chain of penicillin G, producing 6-APA and phenylacetic acid as byproducts.Despite the importance of this reaction in industrial antibiotic production, conventional methods suffer from various inefficiencies, including enzyme degradation, inconsistent yields, batch variability, and high operating costs.

[0004] Historically, the synthesis of beta-lactam antibiotics was performed using batch processing techniques, in which reactants are added gradually to a reaction vessel, allowing the enzymatic reaction to proceed under controlled conditions. In these traditional systems, penicillin G is added to an aqueous buffer solution containing PGA, and the reaction is allowed to complete before the mixture undergoes product separation and purification. Although batch processing has been the standard approach for decades, it has several limitations that hinder the efficiency and scalability of antibiotic production. One of the major challenges of batch processing is the difficulty of maintaining optimal reaction conditions throughout the process.The enzymatic activity of PGA is highly sensitive to pH, temperature, and substrate concentration, and any fluctuations in these parameters can lead to incomplete conversion, reduced yield, and increased by-product formation. Furthermore, batch processes often require manual intervention, making them labor-intensive and prone to human error.

[0005] In response to the inefficiencies associated with batch processing, continuous-flow bioreactor systems have been developed to improve reaction efficiency and yield. In a continuous-flow system, reactants are continuously fed into a bioreactor containing immobilized PGA, allowing the enzymatic reaction to proceed in a controlled and steady-state environment. Immobilizing PGA on a solid support such as agarose beads or magnetic nanoparticles has been shown to be more enzyme-stable and facilitates continuous operation. These systems offer several advantages over batch processing, including reduced enzyme degradation, higher conversion rates, and improved product consistency. Despite these advantages, however, continuous-flow bioreactors still face several limitations.One of the biggest challenges is enzyme leaching, where immobilized PGA gradually detaches from the support matrix over time, leading to a decline in enzymatic activity and reduced efficiency. Furthermore, continuous-flow systems require precise control of flow rates, pH, and temperature to maintain optimal reaction conditions, necessitating sophisticated monitoring and control mechanisms.

[0006] To address these challenges, researchers have investigated various enzyme stabilization techniques, including cross-linked enzyme aggregates (CLEAs) and enzyme encapsulation methods. In CLEAs, enzyme molecules are cross-linked to form stable aggregates that are resistant to leaching and degradation. This approach has been shown to improve the stability of PGA and prolong its catalytic activity. Enzyme encapsulation in porous materials such as silica or polymeric hydrogels has also been investigated as a means of protecting PGA from denaturation and deactivation. While these strategies have shown promise in laboratory-scale studies, their industrial implementation has been limited due to the high cost of enzyme immobilization and the complexity of scaling these techniques for large-scale production.

[0007] Another approach that has been explored to improve the efficiency of enzymatic synthesis is the use of genetic engineering to enhance the catalytic properties of PGA. By modifying the amino acid sequence of PGA through site-directed mutagenesis, researchers have been able to develop enzyme variants with improved stability, higher substrate affinity, and increased resistance to inhibitors. These genetically modified enzymes have demonstrated superior performance compared to wild-type PGA, enabling more efficient conversion of penicillin G to 6-APA. However, the widespread adoption of genetically modified enzymes in drug manufacturing has encountered regulatory challenges and concerns regarding safety, scalability, and cost-effectiveness. The production of recombinant enzymes requires specialized fermentation and purification processes, which can significantly increase production costs.In addition, regulatory authorities impose strict requirements on the use of genetically modified organisms in pharmaceutical production, which limits the feasibility of implementing these enzymes on an industrial scale.

[0008] In addition to enzyme-based approaches, alternative chemical methods for the synthesis of beta-lactam antibiotics have also been investigated. Chemical hydrolysis of penicillin G with strong acids or bases can achieve conversion to 6-APA without the need for enzymatic catalysis. However, chemical hydrolysis methods have several disadvantages, including low selectivity, the formation of undesirable byproducts, and harsh reaction conditions that can disrupt the beta-lactam ring structure. Furthermore, chemical hydrolysis processes generate large amounts of waste and require extensive purification steps to isolate 6-APA, making them less environmentally friendly and economical compared to enzymatic methods.

[0009] Despite advances in enzymatic and chemical approaches, the major drawbacks of existing solutions remain enzyme stability, process efficiency, and scalability. Conventional batch processing is inefficient and labor-intensive, continuous-flow bioreactors suffer from enzyme leaching and complex control requirements, and enzyme immobilization techniques, while promising, are expensive and difficult to implement at scale. Genetically engineered enzymes offer improved catalytic properties but face regulatory and cost hurdles, while chemical hydrolysis methods are non-selective and generate excessive waste. Given these challenges, there is a strong need for a novel system that integrates real-time monitoring, adaptive control mechanisms, and enzyme regeneration strategies to optimize the enzymatic synthesis of beta-lactam antibiotics from penicillin G.

[0010] The present invention aims to overcome these limitations by providing an advanced, automated system that ensures optimal reaction conditions, improves enzyme stability, and maximizes yield. By integrating real-time sensors, AI-driven process optimization, and an enzyme regeneration mechanism, the system maintains continuously high efficiency while minimizing enzyme degradation and operating costs. The inclusion of a self-regulating control unit dynamically adjusts reaction parameters based on real-time feedback, ensuring stable pH, temperature, and substrate concentration throughout the process. Furthermore, a novel enzyme immobilization and regeneration strategy extends the lifetime of PGA, reduces the frequency of enzyme replacement, and improves the cost-effectiveness of the system.In addition, an automated product separation and recycling module ensures maximum substrate utilization, further improving overall efficiency.

[0011] The present invention addresses these challenges by introducing a fully automated, real-time optimized enzymatic synthesis system that ensures high efficiency, stability, and scalability for the industrial production of beta-lactam antibiotics. By integrating advanced sensor technology, adaptive control mechanisms, and an innovative enzyme regeneration strategy, this system offers a superior alternative to existing solutions and paves the way for a more sustainable and cost-effective approach to antibiotic production. SUMMARY OF THE INVENTION

[0012] The present invention provides a system for optimizing the enzymatic synthesis of beta-lactam antibiotics from penicillin G. The system comprises a continuous-flow bioreactor with integrated real-time sensors and an intelligent control unit for automatic adjustments. The bioreactor contains immobilized penicillin G acylase (PGA) on a porous matrix, ensuring extended enzyme stability and efficiency. The system uses an adaptive control algorithm that dynamically modulates temperature, pH, reactant flow rates, and enzyme concentration based on real-time feedback from sensors.

[0013] A microfiltration unit is installed downstream to separate the desired product, 6-APA, from byproducts and unreacted substrates. Furthermore, an automated recycling unit reprocesses unconverted penicillin G, thus improving yield. The system also includes an in-situ enzyme regeneration mechanism that minimizes enzyme degradation and extends operational life. By integrating artificial intelligence-based analytics, the system continuously optimizes reaction parameters, reducing variability and ensuring high-purity antibiotic production.

[0014] The main objective of the present invention is to develop a highly efficient and optimized system for the enzymatic synthesis of beta-lactam antibiotics from penicillin G that overcomes the limitations of existing methods while improving productivity, enzyme stability, and cost-effectiveness. The aim of the invention is to create a continuous bioreactor system with integrated real-time monitoring and adaptive control mechanisms to maintain optimal reaction conditions throughout the entire enzymatic process. By ensuring precise control of temperature, pH, reactant concentration, and enzyme activity, the system eliminates batch-to-batch variations and improves the overall yield of 6-aminopenicillanic acid (6-APA), a crucial intermediate in semi-synthetic antibiotic synthesis.

[0015] Another important objective of the invention is the integration of an advanced enzyme immobilization and regeneration strategy to extend the operational lifetime of penicillin G acylase (PGA), reduce enzyme degradation, and minimize the frequency of enzyme replacement. Immobilizing PGA on a stable porous matrix prevents enzyme leaching while facilitating repeated use in continuous production cycles. Furthermore, an in-situ enzyme regeneration mechanism regularly restores enzyme activity, ensuring sustained efficiency over extended operation. This feature significantly lowers enzyme consumption, reduces production costs, and improves the economic feasibility of large-scale antibiotic production.

[0016] The invention also aims to integrate an automated substrate recycling and product separation system to maximize resource utilization and minimize waste. By continuously recirculating unconverted penicillin G and removing byproducts such as phenylacetic acid, the system improves substrate conversion rates and prevents the accumulation of inhibitors, resulting in a higher yield of 6-APA. The implementation of a microfiltration-based separation unit enables efficient recovery and purification of the final product, ensuring pharmaceutical purity with minimal need for additional processing.

[0017] Another objective of the invention is to integrate artificial intelligence and machine learning algorithms into the control unit to enable real-time process optimization based on historical data and predictive modeling. Through continuous analysis of process variables, the system dynamically adjusts reaction parameters to compensate for fluctuations in enzyme activity, substrate concentration, and ambient conditions. This intelligent control mechanism not only increases production efficiency but also reduces operational variability, ensuring consistent product quality across multiple production cycles.

[0018] Furthermore, the invention aims to develop a scalable and modular system that can be easily integrated into existing pharmaceutical production processes. The system's design allows for seamless expansion depending on production needs, making it suitable for both laboratory-scale research applications and large-scale industrial antibiotic production. Its compact footprint and energy-efficient operation further contribute to sustainability and cost reduction, making it an ideal solution for antibiotic manufacturers seeking to optimize their production processes.

[0019] In summary, the invention is designed to address the critical challenges associated with conventional enzymatic synthesis methods by providing a robust, automated, and highly efficient system for the production of beta-lactam antibiotics. Through real-time monitoring, adaptive process control, enzyme immobilization and regeneration, automated product separation, and AI-driven optimization, the system delivers higher productivity, lower costs, and improved product quality, ultimately transforming the efficiency and scalability of antibiotic manufacturing. SHORT DESCRIPTION OF THE FIGURE

[0020] These and other features, aspects, and advantages of the present invention will become more readily understood when the following detailed description is read in conjunction with the accompanying drawings, in which like characters represent like parts throughout. Fig. Figure 1 shows a block diagram of a system for optimizing the enzymatic synthesis of the beta-lactam antibiotic from penicillin G.

[0021] Furthermore, those skilled in the art will appreciate that elements in the drawings are shown for convenience and may not necessarily be drawn to scale. For example, the flowcharts illustrate the method by key steps to enhance understanding of aspects of the present disclosure. Furthermore, with respect to the construction of the device, one or more components of the device may have been represented in the drawings by conventional symbols, and the drawing may show only the specific details relevant to understanding embodiments of the present disclosure in order not to clutter the drawings with details that would be readily apparent to those skilled in the art who would benefit from the description herein. Detailed description of the invention

[0022] To facilitate an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings and described in specific language. It is to be understood, however, that no limitation on the scope of the invention is intended thereby, since such changes and further modifications of the illustrated system and such further applications of the principles of the invention as illustrated therein are contemplated as would normally occur to one skilled in the art to which the invention pertains.

[0023] It will be understood by one skilled in the art that the foregoing general description and the following detailed description are exemplary and explanatory of the invention and are not intended to be limiting thereof.

[0024] References in this specification to "one aspect," "another aspect," or similar language mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Therefore, occurrences of the phrase "in one embodiment," "in another embodiment," and similar language throughout this specification may or may not all refer to the same embodiment.

[0025] The terms "comprises," "comprising," or other variations thereof are intended to cover non-exclusive inclusion, such that a process or method comprising a list of steps not only includes those steps, but may also include other steps not expressly listed or inherent in such process or method. Likewise, one or more devices or subsystems or elements or structures or components preceded by "comprises...a" does not preclude, without further limitation, the existence of other devices or other subsystems or other elements or other structures or other components or additional devices or additional subsystems or additional elements or additional structures or additional components.

[0026] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The system, methods, and examples provided herein are for illustrative purposes only and should not be considered limiting.

[0027] Embodiments of the present disclosure will be described in detail below with reference to the accompanying drawings.

[0028] In Fig.1, a block diagram of a system for optimizing the enzymatic synthesis of the antibiotic beta-lactam from penicillin G is shown. The system 100 comprises: an enzymatic bioreactor (102) configured for continuous flow operation, in which penicillin G acylase (PGA) is immobilized on a porous support selected from agarose, functionalized silica nanoparticles, polymeric hydrogels, or magnetic nanoparticles, thereby ensuring prolonged enzyme stability, controlled diffusion, and prevention of enzyme leaching; a sensor array (104) embedded in the bioreactor for real-time monitoring, comprising optical, electrochemical, spectrophotometric, and fluorescence resonance energy transfer (FRET)-based sensors, wherein the sensors continuously measure reaction parameters such as pH, temperature, substrate concentration, enzyme activity, and product formation rate;an adaptive control unit (106) comprising a microprocessor-controlled, artificial intelligence (AI)-based predictive model, wherein the control unit dynamically adjusts the substrate flow rate, buffer composition, temperature regulation, enzyme activity modulation, and pH titration in response to real-time sensor data, thus ensuring optimal enzymatic efficiency and sustained 6-aminopenicillanic acid (6-APA) yield; a microfiltration-based product separation unit (108) downstream of the bioreactor, wherein a selective membrane filtration system isolates 6-APA from unreacted penicillin G and by-products, thus enabling continuous recovery and purification of the desired antibiotic intermediate;an automated substrate recycling module (110), wherein unconverted penicillin G is recovered and reintroduced into the bioreactor through an integrated spectrophotometric quantification system, the system measuring the remaining substrate concentration and dynamically adjusting the recycling flow rates to maximize substrate utilization and minimize waste; an enzyme regeneration module (112) comprising a controlled buffer washing and reactivation mechanism that regularly restores enzymatic activity through stabilizing agents selected from polyols, amino acid derivatives, or cofactor solutions, the regeneration module further including an ultrasonic wave activation system to prevent enzyme aggregation and restore the native conformation of the immobilized PGA;a blockchain-based data logging system (114) in which all process parameters, enzyme activity metrics, reaction conditions, and production yields are recorded in an immutable decentralized ledger, ensuring regulatory compliance, traceability, and process safety; a scalable, modular bioreactor architecture (116) in which multiple interconnected enzymatic reactor units operate in parallel, with each bioreactor independently controlled but synchronized with the central AI-based process optimization module, enabling flexible scalability of production as needed.

[0029] In one embodiment, the enzymatic bioreactor (102) is configured as a multi-chamber reactor, with different reaction conditions prevailing in each chamber. The first chamber operates at a slightly acidic pH for optimal catalytic PGA activity, and subsequent chambers operate under increasingly alkaline conditions to improve 6-APA stabilization and reduce the formation of undesirable byproducts.

[0030] In one embodiment, the immobilized enzyme matrix comprises a hybrid composite of functionalized silica nanoparticles coated with a biocompatible polymer, wherein the polymer improves enzyme retention, prevents aggregation, and stabilizes PGA against shear stress during continuous flow processes.

[0031] In one embodiment, the adaptive control unit (106) further comprises a machine learning model using a recurrent neural network (RNN) architecture, wherein the model continuously refines the response parameters by analyzing historical process data and predicting optimal process adjustments in real time.

[0032] In one embodiment, the enzyme regeneration module (112) further comprises a controlled cycle of exposure to a microfluidic channel containing stabilizing cofactors, wherein the cycle of exposure selectively reverses enzyme deactivation while preserving the integrity of the active site.

[0033] In one embodiment, the microfiltration-based separation unit (108) further comprises a multi-stage membrane configuration, wherein the first membrane selectively removes high molecular weight contaminants and the second membrane operates at a nanofiltration scale to purify the recovered 6-APA to pharmaceutical purity.

[0034] In one embodiment, the automated substrate recycling module (110) comprises a real-time liquid chromatography-based quantification unit, wherein the unit dynamically adjusts the reintroduction ratio of unconverted penicillin G based on the detected substrate concentration and reaction kinetics.

[0035] In one embodiment, the blockchain-based data logging system (114) further includes a smart contract protocol, wherein the protocol automatically verifies and records production quality parameters, enzyme performance metrics, and regulatory compliance checkpoints.

[0036] In one embodiment, the modular bioreactor architecture (116) is equipped with interchangeable reaction chambers, allowing rapid exchange of enzyme cartridges without system downtime, with each cartridge preloaded with immobilized PGA and configured for plug-and-play integration.

[0037] In one embodiment, the control interface includes a cloud-based remote monitoring dashboard where process operators can access real-time production analytics, predictive maintenance alerts, and AI-generated optimization recommendations over a secure network connection.

[0038] The present invention provides an advanced system for optimizing the enzymatic synthesis of beta-lactam antibiotics from penicillin G, integrating real-time monitoring, adaptive control, enzyme stabilization, and automated process management to improve efficiency and yield. The system consists of a continuous enzymatic bioreactor in which penicillin G acylase (PGA) is immobilized on a porous matrix to prevent enzyme leaching and improve catalytic stability. The immobilization matrix is ​​selected from agarose, functionalized silica nanoparticles, polymeric hydrogels, or magnetic nanoparticles, enabling precise control of substrate diffusion and enzyme-substrate interaction.Continuous operation of the bioreactor ensures a stable reaction environment, eliminating batch-to-batch variations and improving the overall efficiency of the process.

[0039] A key component of the invention is the sensor array for real-time monitoring, which continuously tracks reaction parameters such as pH, temperature, enzyme activity, substrate concentration, and product formation rates. The sensor array includes optical, electrochemical, spectrophotometric, and fluorescence resonance energy transfer (FRET)-based sensors that enable precise measurements of the kinetics of enzymatic reactions. The FRET-based enzyme activity sensor enables real-time conformational analysis of immobilized PGA and provides important data on enzyme stability and performance. The collected sensor data is transmitted to the adaptive control unit, which serves as the decision-making core of the system.

[0040] The adaptive control unit is a microprocessor-controlled artificial intelligence (AI) module equipped with a machine learning-based predictive model. The control algorithm uses a recurrent neural network (RNN) architecture, specifically a long short-term memory (LSTM) model, to continuously refine reaction conditions by analyzing historical process data and predicting optimal process adjustments. The AI-driven model goes through three main phases: initial calibration, continuous adaptive optimization, and anomaly detection with corrective actions. During the initial calibration phase, the system establishes a baseline reaction dataset by running predefined conditions and recording enzyme efficiency, substrate conversion rates, and product yields.Once the dataset is created, the system enters the continuous adaptive optimization phase, where real-time data is continuously analyzed to predict enzyme degradation trends, substrate depletion rates, and the formation of undesirable byproducts. Using Bayesian optimization and reinforcement learning techniques, the AI ​​model dynamically adjusts reactant flow rates, buffer composition, temperature, and pH regulation to maintain optimal reaction kinetics.

[0041] The anomaly detection and corrective action phase uses an autoencoder-based deep learning approach to detect deviations from expected reaction profiles. The AI ​​system continuously monitors the bioreactor for unexpected changes in enzyme activity, pH shifts, or substrate accumulation that could indicate process instability. When an anomaly is detected, the system automatically implements corrective actions, such as adjusting buffer flow rates, increasing enzyme regeneration frequency, or changing the reaction temperature, to compensate for the deviation. This self-correcting mechanism ensures continuous process stability and prevents unexpected downtime.

[0042] A crucial aspect of the invention is the enzyme regeneration module, designed to prolong PGA activity and reduce the need for frequent enzyme replacements. The module uses a controlled buffer wash and reactivation cycle, in which immobilized PGA is regularly exposed to stabilizing agents such as polyols, amino acid derivatives, or cofactor solutions. Furthermore, the regeneration cycle includes an ultrasonic activation system that applies low-frequency ultrasonic waves to disrupt enzyme aggregation and restore the integrity of the active site. The regeneration frequency is determined by the AI ​​control unit based on real-time enzyme activity data, ensuring that enzymatic degradation is mitigated before performance deteriorates.

[0043] To optimize product purity and yield, the invention comprises a microfiltration-based separation unit positioned downstream of the enzymatic bioreactor. The multi-stage membrane configuration consists of an initial high-molecular-weight filtration membrane that removes enzyme particles and reaction residues, followed by a nanofiltration stage that isolates pharmaceutical-grade 6-aminopenicillanic acid (6-APA). The purified product is then collected for further processing, while unreacted penicillin G is fed into the automated substrate recycling module.

[0044] The substrate recycling module dynamically recirculates unconverted penicillin G into the bioreactor using a real-time liquid chromatography-based quantification system. The chromatography system precisely measures residual substrate concentrations in the wastewater stream, allowing the AI ​​model to determine the optimal recycle ratio of unconverted penicillin G. This adaptive recycling process minimizes substrate waste and ensures high overall conversion efficiency.

[0045] A unique feature of the system is its blockchain-based data logging system, which records all process parameters, enzyme activity metrics, reaction conditions, and production yields in a decentralized ledger. The blockchain implementation ensures tamper-proof process records, regulatory compliance tracking, and automated quality assurance verification. The system also includes smart contract protocols that automatically validate production quality parameters and enzyme performance metrics before they are recorded on the blockchain.

[0046] The system architecture is scalable and modular, allowing multiple bioreactor units to operate in parallel. Each bioreactor operates as an independent unit but is synchronized with the central AI-based process optimization module. The modular configuration enables flexible scalability of production as needed while ensuring consistent process control across all units. The bioreactor architecture features interchangeable reaction chambers, allowing enzyme cartridges to be replaced quickly and without system downtime. Each cartridge is preloaded with immobilized PGA and configured for plug-and-play integration, reducing maintenance and improving operational efficiency.

[0047] To improve process control and user experience, the system features a cloud-based remote monitoring dashboard. Through a secure network connection, operators can access real-time production analytics, predictive maintenance alerts, and AI-generated optimization recommendations. The cloud platform enables remote diagnostics and process adjustments, reducing the need for on-site monitoring. Furthermore, the predictive maintenance module uses AI-driven analytics to anticipate component wear and schedule proactive maintenance, minimizing unplanned downtime.

[0048] The invention integrates advanced enzymatic bioprocessing technology with AI-driven process optimization, real-time sensor monitoring, adaptive control algorithms, enzyme regeneration technology, and blockchain-based compliance tracking to improve efficiency, stability, and scalability in the production of beta-lactam antibiotics. Leveraging machine learning, real-time process optimization, automated substrate recycling, and predictive analytics, the system overcomes the limitations of traditional batch and semi-continuous processing methods. This next-generation enzymatic synthesis platform offers pharmaceutical manufacturers a high-yield, cost-effective, and industrially scalable solution, ensuring consistent antibiotic production with superior efficiency and regulatory compliance.

[0049] The proposed system consists of a multi-component structure, including an enzymatic bioreactor, a sensor array, an adaptive control unit, a product separation module, and an enzyme regeneration unit.

[0050] The enzymatic bioreactor is a continuous flow system with immobilized PGA on a porous, hydrophilic support such as agarose or magnetic nanoparticles. The reactor chamber is designed for optimal substrate-enzyme interaction with precise control of reaction kinetics.

[0051] A sensor array embedded in the bioreactor measures pH, temperature, substrate concentration, product yield, and enzyme activity. These sensors transmit data to the adaptive control unit, which uses predictive algorithms to dynamically modulate operating conditions.

[0052] The adaptive control unit consists of a microprocessor-based feedback loop that optimizes reaction efficiency by adjusting the flow rate of penicillin G and buffer solutions. The unit ensures stable pH values ​​through automatic titration of acid or base solutions.

[0053] The product separation module consists of a microfiltration unit that isolates the desired 6-APA from reaction byproducts. A downstream purification step with activated carbon filtration further increases product purity.

[0054] The enzyme regeneration unit incorporates a mechanism for periodically washing and reactivating immobilized PGA, preventing enzyme inactivation due to substrate overload or prolonged use. This feature extends the enzyme's lifetime and reduces operating costs.

[0055] The system begins with the introduction of a controlled flow of penicillin G solution into the enzymatic bioreactor. Immobilized PGA catalyzes the hydrolysis of penicillin G, producing 6-APA and phenylacetic acid as byproducts. Real-time sensors continuously monitor the reaction environment and feed data into the adaptive control unit.

[0056] If deviations from optimal reaction conditions occur, the control unit adjusts temperature, pH, and reactant flow rates to maintain stability. The system's microfiltration module ensures the selective recovery of 6-APA, which is then purified and collected. Residual reactants are recycled to maximize conversion efficiency.

[0057] To maintain sustained enzyme activity, the enzyme regeneration unit regularly rinses the immobilized PGA with a buffer solution containing stabilizing agents, thereby reducing enzyme degradation over time. Furthermore, an AI-driven analytical model refines the reaction parameters based on historical data, further improving yield and consistency.

[0058] A modular, cartridge-based enzyme housing unit allows for easy replacement of immobilized PGA, thus reducing maintenance-related downtime. The system is compact in design and can be easily integrated into existing pharmaceutical production pipelines.

[0059] The user interface consists of a touchscreen panel for manual settings and real-time monitoring, with options for remote access via a cloud-based dashboard. The system operates in a closed-loop configuration, minimizing reagent waste and environmental impact.

[0060] The present invention falls within the field of bioprocess engineering and pharmaceutical biotechnology and specifically relates to the enzymatic synthesis of beta-lactam antibiotics such as amoxicillin and cephalexin from penicillin G. More specifically, the invention relates to the development of an automated, continuous enzymatic bioreactor system equipped with artificial intelligence-based process optimization, enzyme stabilization, and automated product separation to improve the efficiency, yield, and scalability of antibiotic production. The invention integrates enzyme immobilization techniques, real-time sensor monitoring, machine learning algorithms, adaptive process control, and blockchain-based data logging to create a highly optimized and self-regulating enzymatic synthesis platform.The system is applicable in the pharmaceutical, biotechnology, and chemical process industries where large-scale production of beta-lactam antibiotics is required, offering a sustainable and economically viable alternative to conventional batch and semi-continuous synthesis methods. By addressing challenges associated with enzyme stability, process variability, and operational inefficiencies, the invention represents a significant advance in industrial antibiotic production technology.

[0061] The drawings and the foregoing description provide examples of embodiments. Those skilled in the art will recognize that one or more of the described elements may well be combined into a single functional element. Alternatively, certain elements may be separated into multiple functional elements. Elements from one embodiment may be added to another embodiment. For example, orders of the processes described herein may be changed and are not limited to the manner described herein. Furthermore, the actions of any flowchart need not be implemented in the order shown; nor do all actions necessarily need to be performed. Also, those actions that are not dependent on other actions may be performed in parallel with the other actions. The scope of the embodiments is in no way limited by these specific examples.Numerous variations, whether explicitly stated in the specification or not, such as differences in structure, dimensions, and material use, are possible. The scope of the embodiments is at least as broad as indicated in the following claims.

[0062] Advantages, other benefits, and solutions to problems have been described above with reference to specific embodiments. However, the advantages, benefits, solutions to problems, and any components that may cause an advantage or solution to occur or become more apparent are not to be construed as a critical, required, or essential feature or component of any or all of the claims. REFERENCES 100 A system for optimizing the enzymatic synthesis of beta-lactam antibiotics from penicillin G. 102 Enzymatic Bioreactor 104 Sensor Array For Real-Time Monitoring 106 An Adaptive Control Unit 108 Product separation unit based on microfiltration 110 Automated substrate recycling module 112 Enzyme regeneration module 114 Blockchain-based data collection system 116 Scalable, Modular Bioreactor Architecture

Claims

[1] An automated system for the enzymatic synthesis of beta-lactam antibiotics from penicillin G, comprising: an enzymatic bioreactor configured for continuous flow operation in which penicillin G acylase (PGA) is immobilized on a porous support selected from agarose, functionalized silica nanoparticles, polymeric hydrogels, or magnetic nanoparticles, thereby ensuring prolonged enzyme stability, controlled diffusion, and prevention of enzyme leaching; a sensor array embedded in the bioreactor for real-time monitoring, comprising optical, electrochemical, spectrophotometric, and fluorescence resonance energy transfer (FRET)-based sensors, with the sensors continuously measuring reaction parameters such as pH, temperature, substrate concentration, enzyme activity, and product formation rate; an adaptive control unit comprising a microprocessor-controlled, artificial intelligence (AI)-based predictive model, wherein the control unit dynamically adjusts the substrate flow rate, buffer composition, temperature regulation, enzyme activity modulation, and pH titration in response to real-time sensor data, thus ensuring optimal enzymatic efficiency and sustained yield of 6-aminopenicillanic acid (6-APA); a microfiltration-based product separation unit downstream of the bioreactor, in which a selective membrane filtration system isolates 6-APA from unreacted penicillin G and by-products, thus enabling continuous recovery and purification of the desired antibiotic intermediate; an automated substrate recycling module in which unconverted penicillin G is recovered and reintroduced into the bioreactor via an integrated spectrophotometric quantification system, which measures the residual substrate concentration and dynamically adjusts the recycling flow rates to maximize substrate utilization and minimize waste; an enzyme regeneration module comprising a controlled buffer washing and reactivation mechanism that regularly restores the enzymatic activity through stabilizing agents selected from polyols, amino acid derivatives, or cofactor solutions, the regeneration module further comprising an ultrasonic wave activation system to prevent enzyme aggregation and restore the native conformation of the immobilized PGA; a blockchain-based data logging system in which all process parameters, enzyme activity measurements, reaction conditions, and production yields are recorded in an immutable decentralized ledger to ensure regulatory compliance, traceability, and process safety; A scalable, modular bioreactor architecture in which several interconnected enzymatic reactor units operate in parallel. Each bioreactor is independently controlled but synchronized with the central, AI-based process optimization module, enabling flexible, on-demand scalability of production. [2] The system of claim 1, wherein the enzymatic bioreactor is configured as a multi-chamber reactor and different reaction conditions prevail in each chamber, the first chamber operating at a slightly acidic pH for optimal PGA catalytic activity and subsequent chambers operating under increasingly alkaline conditions to improve 6-APA stabilization and reduce the formation of undesirable by-products. [3] The system of claim 1, wherein the immobilized enzyme matrix comprises a hybrid composite of functionalized silica nanoparticles coated with a biocompatible polymer, wherein the polymer improves enzyme retention, prevents aggregation, and stabilizes PGA against shear stress during continuous flow processes. [4] The system of claim 1, wherein the adaptive controller further comprises a machine learning model using a recurrent neural network (RNN) architecture, the model continuously refining the response parameters by analyzing historical process data and predicting optimal process adjustments in real time. [5] The system of claim 1, wherein the enzyme regeneration module further comprises a controlled cycle of exposure to a microfluidic channel containing stabilizing cofactors, the exposure cycle selectively reversing enzyme deactivation while preserving the integrity of the active site. [6] The system of claim 1, wherein the microfiltration-based separation unit further comprises a multi-stage membrane configuration, wherein the first membrane selectively removes high molecular weight contaminants and the second membrane operates at a nanofiltration scale to purify the recovered 6-APA to pharmaceutical grade purity. [7] The system of claim 1, wherein the automated substrate recycling module comprises a real-time liquid chromatography-based quantification unit, the unit dynamically adjusting the reintroduction ratio of unconverted penicillin G based on the detected substrate concentration and reaction kinetics. [8] The system of claim 1, wherein the blockchain-based data logging system further includes a smart contract protocol, the protocol automatically verifying and recording production quality parameters, enzyme performance metrics, and regulatory compliance checkpoints. [9] The system of claim 1, wherein the modular bioreactor architecture is equipped with interchangeable reaction chambers allowing rapid exchange of enzyme cartridges without system downtime, each cartridge being pre-loaded with immobilized PGA and configured for plug-and-play integration. [10] The system of claim 1, wherein the control interface comprises a cloud-based remote monitoring dashboard where process operators can access real-time production analytics, predictive maintenance alerts, and AI-generated optimization recommendations via a secure network connection.

Images